Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Recent & Breaking News (NYSEAM:TOVX)

Synthetic Biologics to Report 2021 First Quarter Operational Highlights and Financial Results on May 5, 2021

PR Newswire April 28, 2021

Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

PR Newswire April 14, 2021

Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase

PR Newswire April 1, 2021

Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results

PR Newswire March 4, 2021

Synthetic Biologics to Report 2020 Year End Operational Highlights and Financial Results on March 4, 2021

PR Newswire February 25, 2021

Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol

PR Newswire December 22, 2020

Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American

PR Newswire November 24, 2020

Synthetic Biologics Engages A.G.P./Alliance Global Partners as Advisor to Assist in Evaluating Strategic Options

PR Newswire November 16, 2020

Synthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors

PR Newswire November 12, 2020

Synthetic Biologics Reports 2020 Third Quarter Operational Highlights and Financial Results

PR Newswire November 10, 2020

Synthetic Biologics to Report 2020 Third Quarter Operational Highlights and Financial Results on November 10, 2020

PR Newswire November 3, 2020

Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients

PR Newswire October 2, 2020

Synthetic Biologics Reports 2020 Second Quarter Operational Highlights and Financial Results

PR Newswire August 6, 2020

Synthetic Biologics Announces FDA Clearance of Investigational New Drug Application for SYN-020 Intestinal Alkaline Phosphatase (IAP)

PR Newswire July 30, 2020

Synthetic Biologics to Report 2020 Second Quarter Operational Highlights and Financial Results on August 6, 2020

PR Newswire July 29, 2020

Synthetic Biologics Announces Submission of IND Application to U.S. FDA for SYN-020 Intestinal Alkaline Phosphatase

PR Newswire June 30, 2020

Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020 to Treat and Prevent Age-Related Metabolic and Inflammatory Diseases

PR Newswire May 27, 2020

Synthetic Biologics Reports 2020 First Quarter Operational Highlights and Financial Results

PR Newswire May 5, 2020

Synthetic Biologics to Report 2020 First Quarter Operational Highlights and Financial Results on May 5, 2020

PR Newswire April 28, 2020

Startup by Silicon Valley Nobel Protege Invents Compact Home Device with Blockchain Technology Capable of Detecting Coronavirus

ACN Newswire March 21, 2020